ImmuCell Corporation Stock price

Equities

ICCC

US4525253062

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
5.3 USD +0.19% Intraday chart for ImmuCell Corporation +4.13% +4.13%
Sales 2021 19.24M Sales 2022 18.57M Capitalization 47.26M
Net income 2021 - Net income 2022 -2M EV / Sales 2021 3.22 x
Net Debt 2021 89.03K Net Debt 2022 6.69M EV / Sales 2022 2.91 x
P/E ratio 2021
-776 x
P/E ratio 2022
-18.9 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 71.13%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : ImmuCell Corporation, Q4 2023 Earnings Call, Feb 28, 2024
ImmuCell Corporation Enters into an Allonge to and Amendment of Line of Credit with Gorham Savings Bank CI
ImmuCell Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ImmuCell Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
ImmuCell Corporation Announces Unaudited Sales Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Transcript : ImmuCell Corporation, Q3 2023 Earnings Call, Nov 14, 2023
ImmuCell Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Immucell Corporation Reports Preliminary Unaudited Sales Results for the Third Quarter, Nine Months and Trailing Twelve Months Ended September 30, 2023 CI
Transcript : ImmuCell Corporation, Q2 2023 Earnings Call, Aug 11, 2023
ImmuCell Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Immucell Corporation Reports Preliminary Unaudited Sales Results for the Second Quarter, Six Months and Twelve Months Ended June 30, 2023 CI
ImmuCell Adjusts US FDA Submission Schedule for Re-Tain MT
ImmuCell Corporation Appoints Bryan K. Gathagan to Board of Directors CI
ImmuCell Corporation Announces Approval of Principal Terms of $3 Million Debt Facility CI
Transcript : ImmuCell Corporation - Shareholder/Analyst Call
More news
1 day+0.19%
1 week+4.13%
Current month+0.38%
1 month+3.11%
3 months+12.53%
6 months-0.93%
Current year+4.13%
More quotes
1 week
5.01
Extreme 5.01
5.44
1 month
4.94
Extreme 4.94
5.47
Current year
4.71
Extreme 4.71
5.59
1 year
4.26
Extreme 4.26
6.05
3 years
4.26
Extreme 4.26
11.06
5 years
0.00
Extreme 0
13.20
10 years
0.00
Extreme 0
13.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 89-08-31
Director/Board Member 48 09-12-31
Corporate Officer/Principal 68 16-04-04
Members of the board TitleAgeSince
Chief Executive Officer 63 89-08-31
Chairman 67 06-12-20
Director/Board Member 48 09-12-31
More insiders
Date Price Change Volume
24-03-28 5.3 +0.19% 14 713
24-03-27 5.29 +2.52% 13,074
24-03-26 5.16 -1.71% 2,120
24-03-25 5.25 +0.38% 11,358
24-03-22 5.23 +2.75% 3,571

Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT

More quotes
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line, providing Immediate Immunity for the prevention of scours in newborn dairy and beef calves. It expanded this line into four different products with formulations targeting E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. This product line provides Immediate Immunity to newborn calves. The Company is engaged in the development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. The Company's products reduce the use of traditional antibiotics in food producing animals.
More about the company
  1. Stock
  2. Equities
  3. Stock ImmuCell Corporation - Nasdaq